Curated News
By: NewsRamp Editorial Staff
May 27, 2025
Nutriband CEO Discusses AVERSA(TM) Platform in BioMedWire Podcast
TLDR
- Nutriband aims to close the care gap by improving safety while maintaining accessibility in transdermal drug delivery systems.
- Nutriband's AVERSA(TM) platform is designed to deter abuse of opioid patches by making them difficult to manipulate for non-medical use.
- Nutriband's focus on pain management aims to provide effective medications in response to the opioid crisis, improving patient access to care.
- The dramatic contraction in the fentanyl patch market despite the persistent patient population needing these therapies highlights Nutriband's impactful innovation.
Impact - Why it Matters
This news matters as it sheds light on Nutriband's innovative solution to the opioid crisis in pain management. The development of AVERSA(TM) showcases the company's commitment to addressing the challenges faced by pain patients and the healthcare industry as a whole.
Summary
Nutriband (NASDAQ: NTRB) is featured in The BioMedWire Podcast, where Co-Founder and CEO Gareth Sheridan discusses the company's focus on transdermal drug delivery systems, particularly in pain management. Sheridan introduces AVERSA(TM), Nutriband’s platform designed to deter abuse of opioid patches. The interview highlights Nutriband's aim to improve safety while maintaining accessibility in the fentanyl patch market.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband CEO Discusses AVERSA(TM) Platform in BioMedWire Podcast
